A phase 2a, 2-part, open-label, non-randomized, multicenter, single and multiple dose trial to evaluate Pharmacokinetics, Safety and Tolerability of Aztreonam and Avibactam plus or minus Metronidazole in neonates and infants from birth to less than 9 months of age with suspected or confirmed infections due to Gram-Negative pathogens requiring intravenous antibiotic treatment. - NIL

开始日期2024-12-09

申办/合作机构

Pfizer Ltd. (India)

CTR20233317

/ Recruiting临床2期

一项在患有严重革兰阴性菌感染（包括复杂性腹腔内感染）的9 月龄至18 岁以下儿童受试者中研究氨曲南-阿维巴坦静脉给药联用或不联用甲硝唑与最佳可用治疗（BAT）相比的药代动力学、安全性、耐受性和有效性的IIa 期、多中心、观察者设盲、随机双臂研究

该研究拟使用的生物样本来自于确诊为严重革兰阴性菌感染的受试者。本研究的研究目的为在 9 月龄至<18 岁受试者中评估 ATM－AVI用于治疗严重革兰阴性菌感染的 PK 和在 9 月至<18岁受试者中评估 ATM－AVI 和BAT用于治疗严重革兰阴性菌感染的安全性和耐受性及疗效，拟使用全血、血清等人类遗传资源进行分析和检测。

开始日期2024-07-24

申办/合作机构

Pfizer Inc.

[+2]

CTRI/2024/04/065863

/ Not yet recruiting临床1期IIT

Comparing the efficacy of ceftazidime avibactum plus aztreonam therapy versus meropenem polymyxin combination therapy for gram negative sepsis by metallo-beta-lactamase producers in intensive care unit:A randomised control trial - NIL

开始日期2024-04-26

申办/合作机构-

100 项与氨曲南相关的临床结果

登录后查看更多信息

100 项与氨曲南相关的转化医学

登录后查看更多信息

100 项与氨曲南相关的专利（医药）

登录后查看更多信息

8,936

项与氨曲南相关的文献（医药）

2026-02-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Rapid detection of susceptibility to the ceftazidime-avibactam/aztreonam combination and cefiderocol in MBL-producing Enterobacterales by MALDI-TOF MS and turbidimetry

Article

作者: Torres, Ignacio ; Camacho, Jorge ; Colomina, Javier ; Cano, Sofía ; Belizón, Blanca ; Sánchez, David ; Navarro, David ; Poirel, Laurent ; de Michelena, Paula

INTRODUCTION:

Metallo-β-lactamase (MBL)-producing Enterobacterales pose a critical therapeutic challenge due to limited treatment options and high associated mortality. Aztreonam (ATM) combined with avibactam (AVI) and cefiderocol (FDC) are the recommended treatment strategies; however, standard methods for assessing aztreonam/ceftazidime-avibactam (ATM-CZA) synergy and FDC susceptibility are time-consuming and not widely implemented. In this context, the objective of this study was to evaluate whether matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) and turbidimetry could serve as rapid, reliable tools for assessing susceptibility to ATM-CZA and FDC in MBL-producing Enterobacterales.

METHODS:

Thirty-eight clinical MBL-producing isolates were tested. Potential ATM-CZA synergy and FDC susceptibility were assessed using a broth disk elution protocol adapted for MALDI-TOF MS and turbidimetric analysis. Results were compared against reference methods: cross-gradient strips for synergy and EUCAST-standardized techniques for FDC susceptibility. Agreement, sensitivity, specificity, and ROC analyses were performed.

RESULTS:

MALDI-TOF MS achieved 100 % categorical agreement (CA) with the reference method for synergy detection after eight hours of incubation using standard inoculum. FDC susceptibility was correctly identified with 87 % CA within six to eight hours. Turbidimetry also showed strong performance, with up to 93.3 % CA for susceptibility to the ATM-CZA combination and 91.3 % for FDC, demonstrating statistically significant discrimination in absorbance values at six to eight hours.

CONCLUSION:

MALDI-TOF MS and turbidimetry offer accurate and rapid alternatives for the phenotypic detection of susceptibility to the ATM-CZA combination and FDC in MBL-producing Enterobacterales. These methods may enhance early antimicrobial decision-making in clinical microbiology laboratories.

2025-12-31·Virulence

Multifaceted quorum-sensing inhibiting activity of 3-(Benzo[d][1,3]dioxol-4-yl)oxazolidin-2-one mitigates Pseudomonas aeruginosa virulence

Article

作者: Wen, Fulong ; Zhao, Kelei ; Gou, Shiyi ; Chu, Yiwen ; Ma, Wenbo ; Wu, Yi ; Ran, Qiman

As antibiotic resistance escalates into a global health crisis, novel therapeutic approaches against infectious diseases are in urgent need. Pseudomonas aeruginosa, an adaptable opportunistic pathogen, poses substantial challenges in treating a range of infections. The quorum-sensing (QS) system plays a pivotal role in orchestrating the production of a large set of virulence factors in a cell density-dependent manner, and the anti-virulence strategy targeting QS may show huge potential. Here, we present a comprehensive investigation into the potential of the synthesized compound 3-(benzo[d][1,3]dioxol-4-yl)oxazolidin-2-one (OZDO, C₁₀H₉NO₄) as a QS inhibitor to curb the virulence of P. aeruginosa. By employing an integrated approach encompassing in silico screening, in vitro and in vivo functional identification, we elucidated the multifaceted effects of OZDO. Molecular docking predicted that OZDO interfered with three core regulatory proteins of P. aeruginosa QS system. Notably, OZDO exhibited significant inhibition on the production of pyocyanin, rhamnolipid and extracellular proteases, biofilm formation, and cell motilities of P. aeruginosa. Transcriptomic analysis and quantitative real-time PCR displayed the down-regulation of QS-controlled genes in OZDO-treated PAO1, reaffirming the QS-inhibition activity of OZDO. In vivo assessments using a Caenorhabditis elegans-infection model demonstrated OZDO mitigated P. aeruginosa pathogenicity, particularly against the hypervirulent strain PA14. Moreover, OZDO in combination with polymyxin B and aztreonam presented a promising avenue for innovative anti-infective therapy. Our study sheds light on the multifaceted potential of OZDO as an anti-virulence agent and its significance in combating P. aeruginosa-associated infections.

2025-12-31·Emerging Microbes & Infections

Whole-genome analysis of NDM-producing Providencia hangzhouensis associated with recurrent bacteraemia with rapid development of aztreonam-avibactam resistance

Article

作者: Chew, Ka Lip ; Lye, Priscillia ; Bakar, Nur Aisyah Binte Abu ; Cruz Cabang, Joey ; Tan, Ker Xin ; Qiao, Yuan ; Teo, Jeanette

A 60-year-old male with recurrent bacteremia associated with necrotizing pancreatitis was followed over 17 months, during which six clinical isolates of Providencia were obtained. The index isolate (R1) was susceptible to aztreonam-avibactam (MIC 4 mg/L), but resistance (MIC >64 mg/L) emerged with isolate B1, collected one month later, and persisted in subsequent isolates. To investigate the genomic and phenotypic evolution of six Providencia clinical isolates, focusing on mechanisms underlying the emergence of aztreonam-avibactam resistance. Whole-genome sequencing was performed to determine species identity, phylogenetic relationships, and resistance determinants. Average nucleotide identity (ANI) and in silico DNA-DNA hybridization (DDH) were used to confirm species classification. Comparative genomic analysis with R1 as a reference identified mutations associated with resistance. Structural modelling assessed the functional impact of key mutations. All isolates were sequence type ST44. Phylogenomic analysis revealed the isolates were more closely related to Providencia hangzhouensis than P. rettgeri, supported by ANI (97%) and DDH (76%). All isolates harboured bla_NDM-1, correlating with carbapenem resistance. Resistant isolates displayed a glycine insertion at position 420 in PBP3 (p.Gly420dup), which structural modelling indicated disrupted aztreonam-avibactam binding. A Gly151Asp substitution in OmpC was also identified, potentially affecting drug permeability. No mutations were observed in other porins (OmpA, OmpD, or OmpW). This study identifies a glycine insertion in PBP3 as a novel mechanism driving aztreonam-avibactam resistance in Providencia, supported by structural modelling and additional mutations in OmpC. This study provides evidence of a novel resistance mechanism to aztreonam-avibactam in Providencia, driven by a glycine insertion in PBP3 and supported by alterations in OmpC.

112

项与氨曲南相关的新闻（医药）

2025-11-17

·北京医学感染与传染研究

抗菌化疗杂志 80卷 7-11期、增刊2、4期

Journal of Antimicrobial Chemotherapy Volume 80, Issue 7抗菌化疗杂志 80卷 7期 https://academic.oup.com/jac/issue REVIEWS（综述） 1 The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review 抗生素预防用药在前列腺、乳腺及妇科癌症近距离治疗中的作用：叙述性综述 Konstantinos Alexakis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1753–1771, 2 To be or not to be: the non-antimicrobial properties of common antimicrobials 生存还是毁灭：常见抗菌药物的非抗菌特性 Shivakumar Narayanan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1772–1783, SYSTEMATIC REVIEWS（系统综述） 3 Antibiotic-induced Bartter-like syndrome: a systematic review 抗生素诱发的巴特综合征样表现：系统综述 Megha Priyadarshi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1784–1791, 4 Liposomal amphotericin B prophylaxis in paediatrics: a systematic review 两性霉素B脂质体预防性用药在儿科中的应用：系统综述 Emma V Thorley and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1792–1802, ORIGINAL RESEARCH（论著） 5 Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study 婴儿期呼吸道合胞病毒感染所致抗生素使用情况——一项国际前瞻性出生队列研究 Sarah F Hak and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1803–1812, 6 Plasmodium falciparum isolates: ex vivo drug response 恶性疟原虫分离株：体外药物反应 Edem Adika and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1813–1822, 7 Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia 低白蛋白血症对接受厄他培南联合疗法治疗甲氧西林敏感金黄色葡萄球菌菌血症患者的影响 Sunish Shah and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1823–1827, 8 Exploring community pharmacy professionals and general practitioners’ views on primary care communication and pathways to access antibiotics in England 探究英国社区药房专业人员和全科医生对初级保健沟通及获取抗生素途径的看法 Ming Xuan Lee and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1828–1836, 9 Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study 新冠疫情后铜绿假单胞菌菌血症抗菌药物耐药性的下降：一项纵向观察研究 Yulia Butscheid and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1837–1848, 10 Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 意大利HIV感染者（HIV-RNA不可检测）特定合并症与抗逆转录病毒药物转换概率：一项回顾性分析 Alessandro Cozzi-Lepri and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1849–1859, 11 Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia model 基于模型转化利奈唑胺和万古霉素对甲氧西林耐药金黄色葡萄球菌的药代动力学-药效学关系：从体外时间杀菌实验到小鼠肺炎模型 Diego Vera-Yunca and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1860–1868, 12 Inner-mitochondrial membrane protein PfMPV17 is linked to P. falciparum in vitro resistance to the indoloquinolizidine alkaloid alstonine 线粒体内膜蛋白PfMPV17与恶性疟原虫对吲哚醌啉生物碱阿尔斯通宁的体外耐药性相关 J R Macdonald and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1869–1877, 13 Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium 米诺环素与甲硝唑联合治疗大环内酯类耐药生殖支原体感染的疗效和耐受性 Kay Htaik and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1878–1884, 14 Early use of the novel antifungal rezafungin: a case series and literature review 新型抗真菌药物瑞扎芬净的早期使用：病例系列报道及文献综述 H C Davidson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1885–1892, 15 Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach 基于群体药代动力学-药效学模型方法确定阿莫西林在肥胖和胃旁路术后患者中的最佳剂量 Gisela Myrian de Lima Leite Dalla Rosa and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1893–1901, 16 Decreasing antimicrobial resistance in representative UK livestock species was associated with reduced total sales of antimicrobials in the last decade 过去十年，英国代表性家畜物种抗菌药物耐药性下降与抗菌药物总销量减少相关 Aliya El Nagar and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1902–1906, 17 An improved multiplex RT–quantitative PCR assay can reveal sex-specific activity of transmission-blocking drugs on ex vivo gametocytes from Plasmodium falciparum asymptomatic infections 一种改进的多重逆转录定量聚合酶链反应检测法可揭示性特异性抗疟疾传播阻断药物对恶性疟原虫无症状感染体外配子体活性的影响 Mariagrazia Ciardo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1907–1914, 18 Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients 利奈唑胺在肝移植受者中的群体药代动力学及血小板减少症风险评估 Xiaoping Shi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1915–1925, 19 Rapid susceptibility testing on urine for antimicrobial stewardship in general practice 全科实践中的尿液快速药敏试验助力抗菌药物管理 Patrick D J Sturm and Tanja Schülin Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1926–1932, 20 Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains 利奈唑胺单药治疗每12小时一次与每8小时一次，以及与达托霉素联合治疗甲氧西林耐药和糖肽中介金黄色葡萄球菌菌株所致实验性心内膜炎的疗效 María-Alexandra Cañas and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1933–1941, 21 In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains 新型作用机制抗菌药物NOSO-502对包括多重耐药菌株在内的肠杆菌科临床菌株的体外活性 Marie L G Attwood and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1942–1946, 22 Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions 中性及弱酸性条件下，丙二醇对金黄色葡萄球菌和表皮葡萄球菌的抗菌活性 Nadiia Mosiichuk and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1947–1950, 23 Molecular characteristics of chromosome-mediated colistin resistance in foodborne Salmonella isolates in China 中国食源性沙门氏菌分离株染色体介导的多粘菌素耐药性的分子特征 Zeqiang Zhan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1951–1963, 24 High azole non-wild type rates and nosocomial microsatellite typing aggregation of Wickerhamomyces anomalus in China according to a 12-year multicenter surveillance study 根据一项为期12年的多中心监测研究，中国异常威克汉姆酵母属唑类非野生型率高且医院内微卫星分型聚集 Zhengyu Luo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1964–1971, 25 Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus 抗疟药物再利用：乙胺嘧啶对加德纳菌的体外活性优于甲硝唑，且对乳酸杆菌无影响 Aliona S Rosca and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1972–1979, 26 Clinical characteristics and risk factors of tigecycline-induced acute pancreatitis in kidney transplant recipients: a retrospective study 肾移植受者替加环素诱发急性胰腺炎的临床特征及危险因素：一项回顾性研究 Lijuan Feng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1980–1987, 27 Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875 多重耐药鲍曼不动杆菌全球克隆1型参考菌株A297/RUH875的基因组特征 Jonathan Koong and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1988–1992, 28 Comparison of a modified broth microdilution Sensititre™ SLOMYCOI assay with the CLSI-recommended agar disk elution method for antimicrobial susceptibility testing of Mycobacterium haemophilum 改良肉汤微量稀释Sensititre™ SLOMYCOI检测法与CLSI推荐的琼脂稀释法对嗜血杆菌属抗菌药物敏感性检测的比较 Doris Hillemann and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1993–1996, 29 Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations 由于细菌噬菌体和抗生素在临床可达到浓度下的体外协同作用，多重耐药碳青霉烯酶产生肺炎克雷伯菌临床分离株的表型耐药性发生逆转 Paschalis Paranos and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1997–2006, 30 Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France 瑞典和法国假体关节感染表皮葡萄球菌的抗生素耐药性和群体结构 Sofie M Edslev and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2007–2015, 31 Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections 抗生素锁疗法与导管拔除术治疗中心血管导管感染的影响评估 Nischal Ranganath and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2016–2024, 32 Real-time FT-IR typing of Klebsiella pneumoniae: a flexible and rapid approach for outbreak detection and infection control 肺炎克雷伯菌实时傅里叶变换红外分型：一种灵活快速的暴发检测和感染控制方法 Ana Beatriz Gonçalves and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2025–2031, 33 Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori 抗生素压力影响幽门螺杆菌产生的细胞外囊泡的分泌和物理化学特性 Paweł Krzyżek and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2032–2043, 34 A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro 生殖支原体体外诱导产生的新型阿奇霉素耐药突变 Teck-Phui Chua and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2044–2050, RESEARCH LETTERS（研究信函） 35 Posaconazole dosing of enteral formulations in infants and young children to achieve therapeutic concentrations 婴儿和幼儿肠内制剂泊沙康唑的给药剂量以达到治疗浓度 Jeffrey Harrington and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2051–2053, 36 Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis 两性霉素B脂质体治疗慢性内脏利什曼病无效的肾移植受者中使用锑剂作为挽救疗法 Natacha Mrozek and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2053–2056, 37 Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis? 头孢唑林是否可用于治疗葡萄球菌性内源性眼内炎？ Alexandra Morin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2057–2058, LETTER TO THE EDITOR（致编辑的信） 38 Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre—a counterpoint 单用替考拉宁治疗肠球菌感染性心内膜炎：一家转诊中心的回顾性和比较研究——反驳观点 Miguel Villamarín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2059–2060, Journal of Antimicrobial Chemotherapy Volume 80, Issue 8 抗菌化疗杂志 80卷 8期 https://academic.oup.com/jac/issue Review(综述) 1 World Health Organisation’s Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: ‘challenges and opportunities’ 世界卫生组织2017年和2024年用以应对全球抗菌药物耐药性危机的细菌病原体优先名单（BPPL）：“挑战与机遇” Vazhayil Hari Krishnaprasad and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2061–2069 Original Research(论著) 2 Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5years of surveillance prior to approval for clinical use (2019–2023) 氨曲南/阿维巴坦对欧洲医疗中心肠杆菌科细菌的活性：临床批准前5年（2019-2023年）监测总结 Helio S Sader and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2070–2079 3 High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid 利奈唑胺唾液治疗药物监测可行性高，但替地唑胺可行性较低：一项健康受试者单剂量研究和一项接受利奈唑胺患者单中心前瞻性探索性研究 Hitoshi Kawasuji and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2080–2091 4 Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium 缩小版中空纤维感染模型的建立与验证及万古霉素对粪肠球菌的药代动力学/药效学分析 Yukitaka Hayashi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2092–2099 5 Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial 为期4个月的氯法齐明方案治疗敏感型肺结核：一项随机临床试验 Nusrat Shafiq and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2100–2108 6 An ex vivo model to determine transmembrane clearance of antimicrobials during continuous renal replacement therapy 用于确定连续性肾脏替代治疗期间抗菌药物跨膜清除率的体外模型 Cole McGrath and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2109–2116 7 Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa 黏液型铜绿假单胞菌纸片扩散法的优化与改进 Aixin Wang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2117–2125 8 HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022 乌干达接受基于多替拉韦抗逆转录病毒方案的HIV感染者中HIV-1耐药性情况：2022年一项基于国家实验室使用剩余病毒载量样本的调查 Christine Watera and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2126–2134 9 Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women 与固定剂量相比，基于体重给药的CAP256V2LS（一种用于女性HIV预防的广谱中和抗体）群体药代动力学研究 Sharana Mahomed and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2135–2144 10 Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study 接受整合酶抑制剂治疗的HIV感染者肠道微生物群与体重增加情况：一项为期五年的纵向研究 Javier García-Abellán and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2145–2157 11 Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model 慢性戊型肝炎病毒感染移植受者利巴韦林给药方案的开发：一项群体药代动力学和药效学模型研究 Midas B Mulder and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2158–2168 12 Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 长效卡博特韦/利匹韦林在病毒受抑制的HIV感染者中的治疗中断有效性和预测因素：来自Icona队列的现实数据 Roberta Gagliardini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2169–2178 13 Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial 病毒受抑制的HIV感染者中，5天用药2天停药（FOTO）方案与每日比克替拉韦/恩曲他滨/丙酚替诺福韦方案的对比：一项初步随机临床试验 Hsin-Yun Sun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2179–2186 14 Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia 青霉素敏感金黄色葡萄球菌菌血症的纸片扩散试验可靠性和分子流行病学研究 Pernilla Kihlberg and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2187–2193 15 Outcomes of ceftriaxone 2g versus 1g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study 住院肺炎患者每日头孢曲松2克与1克疗效对比：一项全国性回顾性队列研究 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2194–2202 16 Oleanolic acid derivative bardoxolone combats multidrug-resistant Staphylococcus aureus by destroying cell membrane and pyruvate metabolism pathway 齐墩果酸衍生物巴多昔隆通过破坏细胞膜和丙酮酸代谢途径对抗多重耐药金黄色葡萄球菌 Yun-Dan Zheng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2203–2213 17 Evaluation of amoxicillin and benzylpenicillin therapy in early-onset neonatal sepsis: a pharmacometric external validation and simulation study 阿莫西林和苄青霉素治疗早期新生儿败血症的评估：一项药效计量学外部验证和模拟研究 Tom C Zwart and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2214–2225 18 48Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial HIV感染者换用多替拉韦加拉米夫定治疗48周身体成分变化：DOLAM随机临床试验的计划子分析 Elisa de Lazzari and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2226–2233 19 The impact of inter-infection time on antimicrobial resistance profiles in women with multiple urinary tract infections over time 多次尿路感染女性患者感染间隔时间对抗菌药物耐药性特征的影响 Trenton Honda and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2234–2240 20 Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales 一种检测产DHA肠杆菌科细菌的新型快速免疫层析法的开发与评估 Christian Moguet and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2241–2246 21 Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes 粪肠球菌菌血症：一项关注临床和微生物学结局风险因素的多中心观察性研究 Matteo Rinaldi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2247–2256 22 Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus 靛红咔唑类化合物作为宿主导向疗法对抗甲氧西林耐药金黄色葡萄球菌细胞内感染 Robin H G A van den Biggelaar and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2257–2268 23 Clinical validation of antimicrobial dosing regimens for continuous renal replacement therapy based on an ex vivo dosing algorithm 基于体外给药算法的连续性肾脏替代治疗抗菌药物给药方案的临床验证 Christina Koenig and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2269–2279 24 Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy 意大利牛犊艰难梭菌分离株中携带cfr(B)和cfr(C)利奈唑胺耐药基因的新型整合性和接合性元件 Andrea Brenciani and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2280–2284 25 Characterization of Carbapenemase-producing Enterobacterales isolated from patients returning from Sub-Saharan Africa, France, 2015–2022 2015-2022年从撒哈拉以南非洲返回的法国患者中分离出的产碳青霉烯酶肠杆菌科细菌的特征 Corentin Poignon and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2285–2294 26 Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections 具有强生物膜形成能力的青霉素敏感ST398型对骨关节感染构成重大威胁 Ye Jin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2295–2304 27 Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB 贝达喹啉、德拉马尼和莫西沙星与不同剂量苏特唑利或德帕唑利联合用药治疗药物敏感型肺结核的心脏安全性 Simon E Koele and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2305–2313 28 Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study 头孢托唑坦/他唑巴坦与美罗培南治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染的对比：一项单中心回顾性现实研究 Dimitrios Basoulis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2314–2322 Research Letters(研究信件) 29 Dalbavancin as chronic suppressive therapy in a patient undergoing monthly apheresis: a case report with therapeutic drug monitoring 达巴万星作为每月进行血浆置换术患者的长期抑制治疗：一项带治疗药物监测的病例报告 Carlo Pallotto and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2323–2324 30 A novel methicillin-resistant Staphylococcus aureus lineage (ST4174) with an uncharacterized SCCmec variant identified in Korean pigs 韩国猪体内发现的一种带有未表征SCCmec变体的新型甲氧西林耐药金黄色葡萄球菌谱系（ST4174） Hyeonwoo Cho and Kun Taek Park Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2325–2326 31 Time fixes everything, but not always: 10years of persistent PI mutations in the absence of pharmacological pressure—a case report 时间能治愈一切，但并非总是如此：无药物压力下持续10年的蛋白酶抑制剂突变——一例病例报告 Layla Pagnucco and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2327–2330 32 Carbapenem resistance in Escherichia marmotae: characterization of IncL plasmids carrying blaOXA-48 土拨鼠埃希菌的碳青霉烯耐药性：携带blaOXA-48的IncL质粒特征 Astrid Rasmussen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2330–2331 Letters to the Editor(致编辑的信) 33 Comment on: Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital 述评：产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究 Jianjun Li and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2332 34 Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a Tertiary University Hospital—right to reply—author’s response 产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究——作者回复 Gulhadiye Avcu Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2332–2333 Corrections(更正) 35 Correction to: Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD) 更正：索非布韦作为黄热病相关内脏热带病（YEL-AVD）暴露后预防用药 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2334 36 Correction to: Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs 更正：维也纳犬体内发现与人相关的大流行性产超广谱β-内酰胺酶大肠杆菌ST38、ST131和ST141谱系 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2335 37 Correction to: GP or ChatGPT? Ability of large language models (LLMs) to support general practitioners when prescribing antibiotics 更正：全科医生还是ChatGPT？大型语言模型（LLM）在全科医生开具抗生素处方时的辅助能力 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2336 Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2 抗菌化疗杂志 80卷增刊2期 https://academic.oup.com/jac/issue SUPPLEMENT (补充) CANWARD 2007-23 加拿大抗感染耐药监测项目（CANWARD）2007-2023年数据/报告 Foreword(前言) 1 The CANWARD studies: Canadian Antimicrobial Resistance Alliance (CARA) Canadian Hospital Ward Antibiotic Resistance Surveillance collection 加拿大抗感染耐药监测项目研究：加拿大抗微生物耐药联盟（CARA）加拿大医院病房耐药性监测数据集 James C Hurley and Jean-Yves Madec Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Page ii1 Supplement Papers(补充论文) 2 Seventeen years of the CANWARD study (2007–23) 加拿大抗感染耐药监测项目研究17年（2007-2023年） George G Zhanel and Heather J Adam Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii2–ii4 3 Gram-positive pathogens from Canadian hospitals: 17years of results from the CANWARD study (2007–23) 来自加拿大医院的革兰氏阳性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023） George G Zhanel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii5–ii14 4 Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23) 来自加拿大医院的革兰氏阴性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023） George G Zhanel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii15–ii26 5 Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23) 加拿大医院耐甲氧西林金黄色葡萄球菌的特征：加拿大抗感染耐药监测项目研究的17年（2007-2023） Anissa Brahami and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii27–ii34 6 Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007–23) 加拿大抗感染耐药监测项目研究中加拿大医院血液培养和呼吸道标本中肺炎链球菌抗微生物药物耐药性和血清型的比较（2007-23） Heather J Adam and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii35–ii44 7 Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23 加拿大医院中产生ESBL的大肠杆菌和肺炎克雷伯菌的比率增加：加拿大抗感染耐药监测项目研究17年，2007-2023 Philippe Lagacé-Wiens and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii45–ii53 8 Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23) 加拿大医院耐厄他培宁肠杆菌的特征：17年的加拿大抗感染耐药监测项目研究（2007-23） Laura F Mataseje and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii54–ii61 9 Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6years of the CANWARD study (2018–23) 加拿大医院耐碳青霉烯假单胞菌的特征：6年的加拿大抗感染耐药监测项目研究（2018-23） Melissa McCracken and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii62–ii71 10 Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007–23) 加拿大患者血液中病原菌的分布和药敏特征：来自加拿大抗感染耐药监测项目研究（2007-23）的结果 Andrew Walkty and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii72–ii82 Journal of Antimicrobial Chemotherapy Volume 80, Issue 9抗菌化疗杂志 80卷 9期 https://academic.oup.com/jac/issue VIEWPOINT（观点） 1 Classifying patients with invasive fungal disease: towards a unified case definition? 侵袭性真菌病患者分类：能否达成统一的病例定义？ Mehmet Ergün and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2337–2343, SYSTEMATIC REVIEW（系统综述） 2 Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis 早期转换为口服抗生素治疗革兰氏阳性菌血流感染的疗效和安全性：一项系统综述和荟萃分析 ZhaoYi Tan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2344–2360, ORIGINAL RESEARCH（论著） 3 Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium 屎肠球菌中那拉霉素、盐霉素、拉沙洛西钠和莫能菌素流行病学临界值的测定 Maria Laura Ferrando and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2361–2368, 4 Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era 四类耐药HIV感染者体内CXCR4嗜性病毒的持续存在及其在现代抗逆转录病毒治疗时代的临床影响 Rebecka Papaioannu Borjesson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2369–2374, 5 Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks 随机试验中96周内使用多替拉韦或对照抗逆转录病毒疗法对高血压和血压变化的影响 Parul Patel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2375–2383, 6 Comparative analysis of lipid profile changes in treatment-naïve people living with HIV on INSTI-based single-tablet regimens, BIC/FTC/TAF and DTG/3TC: real-world evidence from South Korea 基于整合酶抑制剂的单片复方制剂BIC/FTC/TAF和DTG/3TC在韩国初治HIV感染者中血脂谱变化的比较分析：来自现实世界的证据 So Yun Lim and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2384–2390, 7 A novel multilocus sequence typing scheme for Morganella spp.: population structure and introduction of quantitative metric for standardization of MLST scheme 摩根氏菌属的一种新型多位点序列分型方案：群体结构及引入用于标准化多位点序列分型方案的定量度量标准 Aymeric Jacquemin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2391–2398, 8 Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya 2022年肯尼亚霍乱疫情中产超广谱β-内酰胺酶的多重耐药霍乱弧菌O1株的基因组特征 Diana Imoli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2399–2407, 9 Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection 经验性抗万古霉素耐药肠球菌治疗对万古霉素耐药肠球菌血流感染患者生存率的影响 Tao-Hung Ou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2408–2416, 10 Safety of topical tobramycin powder during operative treatment of fractures 骨折手术中使用局部妥布霉素粉末的安全性 Gregory M Schrank and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2417–2420, 11 Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS 复方磺胺甲恶唑与噬血细胞性淋巴组织细胞增多症（HLH）的风险：基于FAERS数据库个案安全报告的文献综述和比例失衡分析 Rinko Lau and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2421–2427, 12 Highly drug-resistant Vibrio cholerae harbouring blaPER-7 isolated from travellers returning to England 从返回英国的旅行者中分离出携带blaPER-7基因的高度耐药霍乱弧菌 Satheesh Nair and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2428–2432, 13 Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics 克服幽门螺杆菌的抗菌药物耐药性：附带敏感性和生物膜动态的作用 Siddharth Singh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2433–2441, 14 Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae 四种未接触过但对头孢地尔耐药的产NDM肺炎克雷伯菌所致血流感染的临床和微生物学分析 Maria Mazzitelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2442–2446, 15 Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo DHA27与庆大霉素联合对耐甲氧西林金黄色葡萄球菌的体内外协同作用 Xuemin Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2447–2458, 16 A multicentre study for determination of epidemiological cut-off values for Candida auris with EUCAST broth microdilution reference methodology 采用EUCAST肉汤微量稀释参考方法进行耳念珠菌流行病学临界值的多中心测定研究 Joseph Meletiadis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2459–2465, 17 Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study 万古霉素耐药对屎肠球菌血流感染归因死亡率的影响：一项大型多中心回顾性研究的倾向评分分析 M Del Monte and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2466–2473, 18 Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient 异基因造血干细胞移植受者中CMV和EBV双重再激活的动态变化及耐药性的出现 Martyna Pociupany and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2474–2483, 19 Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy 意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况 Angelo Roberto Raccagni and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2484–2486, 20 Comparing the mortality of patients with sepsis using empirical piperacillin/tazobactam and cefepime: analysis of the MIMIC-IV database 使用经验性哌拉西林/他唑巴坦和头孢吡肟的脓毒症患者死亡率比较：基于MIMIC-IV数据库的分析 Yongseop Lee and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2487–2495, 21 Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024 2024年中国河南省HIV-1感染者传播耐药情况 Jinjin Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2496–2502, 22 Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance A类碳青霉烯酶基因blaFRI拷贝数的波动似乎赋予了高水平碳青霉烯耐药性 Makiko Noda and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2503–2512, 23 In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization 头孢比罗联合氨苄西林对引起感染性心内膜炎的粪肠球菌的体外活性：表型和基因型特征 Clara Moretó-Castellsaguéand others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2513–2523, 24 Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates 达巴万星与β-内酰胺类药物对心内膜炎相关粪肠球菌临床分离株的矛盾相互作用 David Luque Paz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2524–2529, 25 Comparative evaluation of broth microdilution and gradient diffusion methods in Burkholderia cepacia complex susceptibility testing: implications of transitioning to ECV-based interpretation 伯克霍尔德菌复合群药敏试验中肉汤微量稀释法和梯度扩散法的比较评估：向基于ECV解释转变的影响 Wenjie Cui and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2530–2540, 26 Strengthening antimicrobial resistance diagnostics in National Reference Laboratories across One Health in South and Southeast Asia: impact of external quality assessment and targeted follow-up 加强南亚和东南亚“同一健康”国家参考实验室的抗菌药物耐药性诊断能力：外部质量评估和针对性随访的影响 Freshwork Ayalew Abegaz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2541–2549, RESEARCH LETTERS（研究快信） 27 TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient 治疗药物监测指导下的美罗培南/瓦博巴坦疗法成功治疗儿童肝移植受者中产KPC且对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌引起的腹腔和血流感染 Giovanni Mulé and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2550–2552, 28 Novel tmexC7D2-toprJ5 gene cluster and transposon Tn7759 carrying blaVIM-2 and blaOXA-10 genes in a carbapenem-resistant Pseudomonas putida from urban sewage 城市污水中碳青霉烯耐药恶臭假单胞菌中携带blaVIM-2和blaOXA-10基因的新型tmexC7D2-toprJ5基因簇和转座子Tn7759 Xinyuan Qiu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2552–2555, 29 Characterization of multiresistance gene optrA in Bacillus subtillis from China 中国枯草芽孢杆菌中多重耐药基因optrA的特征分析 Yongliang Che and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2555–2557, 30 Genomic characterization of a multidrug-resistant Mammaliicoccus sciuri strain isolated from urine of a patient from China 从中国患者尿液中分离出的一株多重耐药马氏鼠球菌的基因组特征 Fuqiang Ye and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2558–2560, LETTERS TO THE EDITOR（致编辑的信） 31 Comment on: Isavuconazole therapeutic drug monitoring and association with adverse events 关于“艾沙康唑治疗药物监测及其与不良反应的关联”的评论 Mi Zhou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2561–2562, 32 Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalised patients with pneumonia: a nationwide retrospective cohort study 关于“住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究”的评论 Satoru Mitsuboshi Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Page 2563, 33 Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—authors’ response 住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究——作者回复 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2563–2564, Journal of Antimicrobial Chemotherapy Volume 80, Issue 10抗菌化疗杂志 80卷 10期 https://academic.oup.com/jac/issue REVIEWS（综述） 1 Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead 长效卡博特韦和利匹韦林治疗HIV感染者的现状与未来挑战 Luis Buzón-Martín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2565–2586, 2 Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal 系统综述与《抗菌化疗杂志》：过去、现在与未来——系统再评估 James C Hurley Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2587–2596, SYSTEMATIC REVIEWS（系统综述） 3 Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology 研究肺结核治疗的肺内药代动力学：方法学的系统综述 Isabella van der Feltz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2597–2608, 4 Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis 全球人类中耐呋喃妥因的尿路致病性大肠埃希菌（UPEC）流行率：系统综述与荟萃分析 Christopher Larkin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2609–2621, ORIGINAL RESEARCH（研究论著） 5 Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium? 氨苄青霉素联合头孢菌素是否为氨苄青霉素敏感的粪肠球菌的治疗选择？ Paula Bierge and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2622–2629, 6 Therapeutic efficacy monitoring of pyronaridine–artesunate (Pyramax®) in treating uncomplicated Plasmodium falciparum malaria in Gia Lai province, Vietnam from 2022 to 2023 2022-2023年越南嘉莱省青蒿琥酯-吡咯尼抗（Pyramax®）用于无并发症恶性疟原虫疟疾的治疗效果监测 Nguyen Van Thanh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2630–2634, 7 Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia 哌拉西林/他唑巴坦负荷剂量用于革兰氏阴性菌血症患者延长输注给药的有效性 Savan Patel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2635–2643, 8 Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia 连续输注大剂量头孢比罗在社区获得性肺炎危重患者中的肺内浓度 Claire Roger and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2644–2653, 9 Cefixime versus benzathine penicillin G for the treatment of early syphilis—a randomized, controlled open label trial 头孢克肟与苄星青霉素G治疗早期梅毒的随机对照开放标签试验 Tamara Klementová and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2654–2658, 10 Trends in antifungal use among hospitalized patients in the USA, 2018–23 2018-2023年美国住院患者抗真菌药物使用趋势 Dallas J Smith and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2659–2664, 11 Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study BCID2和快速AST VITEK® REVEALTM对革兰氏阴性菌血流感染危重患者抗生素优化的临床影响：一项准实验性前后干预研究 Louis Oudiane and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2665–2675, 12 In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium 甲砜霉素对药物敏感和耐药生殖支原体菌株的体外活性 Sofie Skovmand and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2676–2681, 13 A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model 基于群体药代动力学模型的左氧氟沙星剂量方案先验优化 Emmanuel Enard and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2682–2692, 14 Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis 危重患者头孢他啶-阿维巴坦的模型知情个体化给药：群体药代动力学研究和参数时间事件分析 Tingting Wu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2693–2704, 15 Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria 开发血培养阳性时间作为监测针对多重耐药革兰氏阴性菌抗生素治疗的药效动力学指标 Irene Zaghi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2705–2713, 16 In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model 头孢布坦-莱达博巴坦口服联合用药对产丝氨酸-β-内酰胺酶肠杆菌科细菌的体内活性评估：在肾盂肾炎和膀胱炎小鼠模型中的评估 Christina Koenig and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2714–2718, 17 Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial 健康受试者静脉注射后口服奥马环素的粪便药代动力学、微生物组和胆汁酸变化：一项1期临床试验 Jinhee Jo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2719–2726, 18 Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application 抗逆转录病毒治疗依从性干血斑检测法的实验室间比对：对临床应用的启示 Nathan Engel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2727–2731, 19 A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study 意大利北部长效注射用卡博特韦和利匹韦林有效性、持久性和安全性的现实中多中心前瞻性队列研究：LONGITUDE研究 Maria Mazzitelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2732–2741, 20 Assessment of the risk of developing cefepime-induced abnormal liver enzyme levels using the albumin–bilirubin score and fibrosis-4 index: a single-centre retrospective case–control study 使用白蛋白-胆红素评分和纤维化-4指数评估头孢吡肟诱导的肝酶水平异常发生风险：一项单中心回顾性病例对照研究 Hiroki Katsu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2742–2751, 21 Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial BALANCE临床试验中血流感染患者的临床病程 Sean W X Ong and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2752–2758, 22 Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study 神经重症患者中多黏菌素治疗碳青霉烯类耐药革兰氏阴性菌肺炎的结果比较：一项回顾性队列研究 Qian Zeng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2759–2772, 23 Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates 肉鸡和人类临床分离的粪肠球菌中NarAB的不同群体结构和基因组背景 Jayanth Balakuntla and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2773–2781, 24 Population pharmacokinetics of bictegravir in real-world people with HIV 现实中HIV感染者比克替拉韦的群体药代动力学 Pierre Ekobena and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2782–2789, 25 Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index 活动性肺结核整个治疗期间利福平浓度：性别和体重指数的影响 Teres Samuelsson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2790–2798, 26 Performance of disc diffusion and gradient strip test on different Mueller–Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa 在碳青霉烯类耐药铜绿假单胞菌中对头孢地尔敏感性测试使用不同穆勒-欣顿琼脂培养基平板和ComASP®及Bruker UMIC®头孢地尔微量稀释板的纸片扩散法和梯度条带测试的性能 Stefano Mancini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2799–2806, 27 Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model 在离体人类绒毛叶模型中治疗COVID-19的药物莫努匹拉韦、法维拉韦和奈玛特韦/利托那韦的胎盘转移 Solene Labaye and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2807–2813, 28 Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms 针对具有多种耐药机制的高度耐药鲍曼不动杆菌患者分离株的含头孢地尔抗生素联合用药的协同作用 Justin Halim and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2814–2824, 29 Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France 2015-2022年药物减量抗逆转录病毒策略的采用情况及对成本的影响：来自法国巴黎一家HIV诊所的经验 L Sagaon-Teyssier and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2825–2833, 30 Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin 对达拉氟沙星敏感的侵袭性临床肺炎链球菌分离株中氟喹诺酮耐药性的分子特征 Emilia Cercenado and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2834–2843, 31 Genomic structure of class 1 and 2 integrons in non-typhoidal Salmonella isolated from food animals and related meat products in the USA 美国食品动物及其相关肉类产品中分离的非伤寒沙门氏菌1类和2类整合子的基因组结构 Chih-Hao Hsu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2844–2853, 32 Characterization of blaOXA-542-mediated carbapenem resistance in Acinetobacter baumannii 鲍曼不动杆菌中blaOXA-542介导的碳青霉烯类耐药性的特征 Jingchen Hao and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2854–2861, 33 Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones 各种诺卡氏菌属临床分离株对碳青霉烯类和氟喹诺酮类的表型和基因型特征 Jing Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2862–2872, RESEARCH LETTERS（研究快报） 34 Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option? 奥利他万星治疗粪肠球菌复发性心内膜炎患者：一种新的治疗选择？ Giulia Turicchi and Marco Bongiovanni Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2873–2874, 35 The catA1 chloramphenicol resistance gene originated in Atlantibacter hermannii catA1氯霉素耐药基因起源于大西洋菌属赫尔曼尼菌 Robert A Moran and Ruth M Hall Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2874–2876, 36 Horizontal transmission of a multidrug-resistant IncM1 plasmid harbouring blaOXA-48 and blaCTX-M-14b among patient microbiotas 携带blaOXA-48和blaCTX-M-14b的多重耐药IncM1质粒在患者微生物群中的水平传播 Roberto Sierra and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2876–2879, 37 Antimicrobial activity of temocillin on ceftriaxone-resistant and ceftriaxone-susceptible isolates of Neisseria gonorrhoeae 替莫西林对头孢曲松耐药和头孢曲松敏感淋病奈瑟菌分离株的抗菌活性 Julie Brousseau and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2879–2881, LETTERS TO THE EDITOR（致编辑的信） 38 Comment on: Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus 述评：抗生素联合用药对临床分离的鸡肠球菌和粪肠球菌的杀菌活性 Karl Oldberg and Magnus Rasmussen Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2882–2883, 39 Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study 述评：住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究 Giancarlo Ceccarelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2884–2885, 40 Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—right to reply—authors’ response 住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究——作者回应权——作者回复 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2885–2886, Journal of Antimicrobial Chemotherapy Volume 80, Issue Supplement_4抗菌化疗杂志 80卷增刊4期 https://academic.oup.com/jac/issue/80/Supplement_4 SUPPLEMENT（补充） Two Decades of BSAC Resistance Surveillance 英国抗菌化疗学会二十年耐药性监测 FOREWORD（前言） 1 Two Decades of BSAC Resistance Surveillance 英国抗菌化疗学会二十年耐药性监测 James C Hurley and Alan P Johnson Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Page iv1, SUPPLEMENT PAPERS（补充论文） 2 Two decades of resistance surveillance by the British Society for Antimicrobial Chemotherapy: design, development, delivery, deficiencies and future directions 英国抗菌化疗学会二十年耐药性监测：设计、发展、实施、不足与未来方向 Alasdair P MacGowan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv2–iv6, 3 The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations 英国抗菌化疗学会耐药性监测项目：方法与局限性 Michael Allen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv7–iv21, 4 Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019 英国和爱尔兰地区革兰氏阳性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv22–iv35, 5 Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019 英国和爱尔兰地区革兰氏阴性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv36–iv48, 6 Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019 英国和爱尔兰地区医院获得性下呼吸道感染病原体的抗菌药物耐药性趋势（2008/2009 - 2018/2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv49–iv59, 7 Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019 英国和爱尔兰地区社区获得性下呼吸道感染病原体的抗菌药物耐药性趋势（1999/2000 - 2018/2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv60–iv71, 8 Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999–2019) 英国和爱尔兰地区肺炎链球菌血清型及耐药性趋势（1999 - 2019年） Carolyne Horner and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv72–iv86, 9 Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project—legacy and future 英国抗菌化疗学会耐药性监测项目的应用与益处——成果与未来 Benjamin J Parcell and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv87–iv95, Journal of Antimicrobial Chemotherapy Volume 80, Issue 11抗菌化疗杂志 80卷 11期 https://academic.oup.com/jac/issue VIEWPOINTS（观点） 1 Modification of antimicrobial susceptibility testing methods 抗菌药物敏感性检测方法的修改 Ian Morrissey and Jean B Patel Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2887–2888, 2 Viewpoint: global antimicrobial stewardship accreditation is needed: the experience in Kentucky, USA 观点：需要建立全球抗菌药物管理认证体系：美国肯塔基州的经验 Ashley M Wilde and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2889–2891, REVIEWS（综述） 3 Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules 噬菌体揭示抗菌药物耐药性的生物学脉络：从起源与传播到替代治疗模式 Cleo Anastassopoulou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2892–2901, 4 Molecular drivers of fusion plasmid: mechanistic insights and evolutionary implications 融合质粒的分子驱动因素：机制见解与进化意义 Ziyi Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2902–2911, ORIGINAL RESEARCH（研究论著） 5 Emergence of livestock-associated MRSA clonal complex 398 in Thailand’s swine industry 泰国养猪业中出现与牲畜相关的MRSA克隆复合体398 Pawarut Narongpun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2912–2917, 6 Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series 长期使用替达拉韦抑制治疗期间出现周围神经病变：系列病例报告 Tomaso Beringheli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2918–2922, 7 Low bacterial metabolism as a central mechanism of antimicrobial resistance and potential therapeutic target of staphylococcal biofilms in ventricular assist device driveline infections 细菌低代谢作为抗菌药物耐药性的核心机制及心室辅助装置驱动线感染中葡萄球菌生物膜的潜在治疗靶点 Yao Sun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2923–2933, 8 The pivotal role of acnA in linking carbon metabolism to virulence and antimicrobial resistance in methicillin-resistant Staphylococcus aureus acnA在连接碳代谢与耐甲氧西林金黄色葡萄球菌的毒力和抗菌药物耐药性中的关键作用 Jiahui Li and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2934–2944, 9 Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study 接受以依非韦伦为基础的抗逆转录病毒治疗的HIV-结核病共感染患者中利福平和异烟肼的药代动力学：ANRS12292-RIFAVIRENZ子研究 Thibaut Gelé and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2945–2953, 10 Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare 胞内分枝杆菌中与氯法齐明耐药相关的新型突变 Xiuzhi Jiang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2954–2957, 11 Physiologically informed in vitro framework reveals context-dependent combinatory activity of niclosamide–colistin against Gram-negative bacteria 基于生理信息的体外框架揭示了针对革兰氏阴性菌的硝基咪唑-多粘菌素组合的情境依赖性活性 Mariana Romero-Gonzalez and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2958–2969, 12 In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin 体外进化揭示生殖支原体对莫西沙星的耐药机制 Teck-Phui Chua and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2970–2977, 13 The toxin–antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening 毒素-抗毒素系统SavRS通过介导细胞壁增厚促进万古霉素中间型金黄色葡萄球菌对万古霉素的耐药性 Weifeng Xu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2978–2988, 14 Molecular insights into carbapenemase-producing Enterobacterales from Senegal 塞内加尔产碳青霉烯酶肠杆菌目细菌的分子特征 Ousmane Sow and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2989–3000, 15 Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients 老年患者中利奈唑胺及其代谢产物PNU-142300的群体药代动力学模型 Xianglong Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3001–3010, 16 In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus: a multicenter study in China 在中国开展的一项多中心研究中，康替唑胺及其他对照药物对临床分离的金黄色葡萄球菌和肠球菌的体外活性 Rongqi Lu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3011–3020, 17 Co-existence of the oxazolidinone resistance genes cfr and optrA on a novel multiresistance plasmid from a methicillin-resistant Macrococcoides bohemicum strain 从一株耐甲氧西林的马科考代菌属波希米亚菌株中发现的携带恶唑烷酮耐药基因cfr和optrA的新型多重耐药质粒 Yao Zhu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3021–3025, 18 Multidrug resistance and recurrence in urinary bacteraemia among cancer patients 癌症患者中尿路菌血症的多药耐药性和复发情况 Ignacio Grafia and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3026–3033, 19 Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection 在严重的体内感染期间，ST11型碳青霉烯耐药且高毒力的肺炎克雷伯菌中blaKPC变体的快速替代导致头孢他啶/阿维巴坦耐药 Ping Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3034–3042, 20 Potential human health risk of carbapenem-non-susceptible Pseudomonas aeruginosa from companion animals 伴侣动物中碳青霉烯类不敏感铜绿假单胞菌对人类健康的潜在风险 Jirachaya Toyting-Hiraishi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3043–3056, 21 Assessment of an LC coupled with tandem MS (LC-MS/MS) tool in the detection of antimicrobial resistance mechanisms in Enterobacterales 液相色谱-串联质谱（LC-MS/MS）工具在检测肠杆菌目细菌抗菌药物耐药机制中的应用评估 Anna Witkowska and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3057–3064, 22 Multidrug efflux pumps and innate azole resistance of Mucor lusitanicus 毛霉属葡萄牙菌的多药外排泵及其固有唑类耐药性 Stephanie Toepfer and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3065–3078, 23 Ivermectin dosing for children under 2 years 2岁以下儿童的伊维菌素剂量 Wenyu Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3079–3081, 24 Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 一线拉米夫定/多替拉韦抗逆转录病毒疗法在HIV感染者中的有效性：来自ICONA基金会队列的现实数据 Alessandra Vergori and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3082–3091, 25 Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic 城市学术型HIV诊所中长效注射用卡博特韦-利匹韦林启动的资格及关联因素 Geoffroy Liegeon and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3092–3100, 26 Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry 在接受抑制性抗逆转录病毒治疗的高度治疗经验丰富和多药耐药个体中，HIV-1 DNA耐药演变的评估：来自PRESTIGIO登记处的纵向研究 D Armenia and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3101–3106, 27 Sequential antibiotic exposure restores antibiotic susceptibility 序贯抗生素暴露恢复抗生素敏感性 Farhan R Chowdhury and Brandon L Findlay Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3107–3117, 28 Dermatological adverse effects of doxycycline as post-exposure prophylaxis for sexually transmitted infections among men who have sex with men: real-world findings from a multicentre study 在男男性行为者中，使用多西环素作为性传播感染暴露后预防的皮肤科不良反应：一项多中心研究的现实发现 Ling-Ya Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3118–3122, 29 Phenotype–genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt 埃及导管相关尿路感染中分离的革兰氏阴性尿路病原菌抗菌药物耐药性表型-基因型不一致性 Mohamed Eladawy and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3123–3132, 30 How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy? 在抗逆转录病毒治疗管理中，应如何考虑APOBEC3诱导的耐药突变？ Marie Gilbert and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3133–3138, 31 In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species 奥洛芬和抗真菌药物组合对曲霉菌和念珠菌属的体外评价 Corinne Pinder and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3139–3149, 32 Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis 在侵袭性肺曲霉病小鼠模型中，泊沙康唑与奥洛芬之间的拮抗作用 Christopher A Darlow and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3150–3159, 33 High level of archived and circulating HIV-1 drug resistance mutations in adolescents with a detectable viremia in Cameroon 喀麦隆可检测到病毒载量的青少年中HIV-1药物耐药突变的存档和循环水平较高 Armando B D Djiyou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3160–3164, RESEARCH LETTERS（研究快讯） 34 SCY-247, a novel second-generation triterpenoid antifungal, demonstrates high in vitro activity against genetically diverse Candida auris isolates, including FKS1 mutants 新型第二代三萜类抗真菌药物SCY-247对包括FKS1突变体在内的多种基因型耳道假丝酵母菌显示出高体外活性 Bram Spruijtenburg and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3165–3166, 35 Drug–drug interactions between tirzepatide and antiretrovirals: time to reassess and reassure? 替西帕肽与抗逆转录病毒药物之间的药物-药物相互作用：是时候重新评估和安心了吗？ Andrea Poloni and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3167–3168, 36 Does the use of topical azoles have an impact on antifungal resistance? 局部使用唑类药物对抗真菌耐药性有影响吗？ Jean-Yves Maillard Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3168–3186, 37 Leakage of cabotegravir and rilpivirine in HIV patients receiving long-acting injectable antiretroviral therapy 接受长效注射用抗逆转录病毒治疗的HIV患者中卡博特韦和利匹韦林的泄漏情况 Samir Benkouiten and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3187–3188, CORRECTION（更正） 38 Correction to: Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae 更正：对四种产NDM且之前未接触过头孢地洛的耐药肺炎克雷伯菌引起的血流感染的临床和微生物学分析 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Page 3189,

2025-11-13

·重症肺言

免疫抑制宿主重症肺部感染的耐药挑战与精准抗感染策略

作者：唐以军，王梅芳单位：十堰市太和医院呼吸与危重症医学科随着医疗技术发展与人均寿命延长，免疫抑制宿主群体比例逐年上升，其重症肺部感染的发病率与死亡率显著高于普通人群，且面临多重耐药菌（MDRO）感染的严峻挑战。本文结合最新临床指南与研究证据，系统阐述免疫抑制宿主的定义与分类、急性呼吸衰竭（ARF）的诊断策略、感染病原体特点、病原学诊断方法、抗感染治疗策略及新型抗耐药菌药物，同时通过临床病例验证诊疗思路，为临床实践提供精准化、个体化的诊疗参考。一、免疫抑制宿主的定义、分类与临床特征 1. 免疫抑制宿主的定义免疫抑制宿主指存在影响免疫系统的潜在疾病（如血液系统肿瘤、HIV/AIDS）或接受免疫抑制治疗（如糖皮质激素、生物制剂），导致肺炎发生风险升高，且不仅易感染常见病原体，还易发生机会性感染的人群。 2. 免疫抑制的分类与状态分级 2.1 免疫抑制类型免疫抑制分为原发性和继发性两类，临床以继发性免疫抑制为主，常见包括实体肿瘤、血液系统肿瘤、器官移植（实体器官移植、造血干脑细胞移植）、长期糖皮质激素使用、接受化疗、使用免疫抑制剂、生物制剂等患者。此外，糖尿病、慢性肺部疾病、肝病、肾病，甚至年老体弱的患者都可以被认为是相对免疫抑制状态。 2.2 免疫状态分级 2025年Lancet Respir Med 杂志发表的综述提出了免疫状态三级分类标准：（1）无典型免疫抑制，但存在易感染基础：包含慢性阻塞性肺疾病（COPD）、肝硬化、终末期肾病、糖尿病、实体恶性肿瘤、妊娠与新生儿等人群。这类人群无明确免疫缺陷，但基础疾病或生理状态会轻度增加感染风险。（2）轻度免疫抑制：涵盖HIV/AIDS（CD4+T细胞＜200个/mm³）、血液系统恶性肿瘤，以及使用特定免疫调节药物（如≤15 mg/d糖皮质激素、吗替麦考酚酸等）的患者。这类人群免疫功能部分受损，易发生机会性感染（如肺孢子菌肺炎、念珠菌病），且术后败血症风险升高。（3）重度免疫抑制：包括HIV/AIDS（CD4+T细胞＜50个/mm³）、造血干细胞移植（2年内）、实体器官移植、中性粒细胞缺乏（＜0.5×109/L）、无脾，以及接受CAR-T细胞治疗、B细胞耗竭治疗（如伊布替尼）的患者。这类人群免疫功能显著受损，易发生严重机会性感染（如隐球菌脑膜炎、巨细胞病毒肺炎），死亡率极高。 2.3 糖皮质激素与免疫抑制的关系 2020年Chest 杂志发表的免疫功能低下成人社区获得性肺炎（CAP）初始治疗策略的专家共识显示：①非免疫抑制人群：强的松剂量≤10 mg/d且累积剂量<600 mg，CAP风险无明显增加；②相对风险升高：强的松剂量10～20 mg/d且累积剂量>600 mg，罹患CAP的风险增加，但仅感染常见病原体（如肺炎链球菌），不归类为免疫抑制人群；③明确的免疫抑制人群：强的松剂量≥20 mg/d且累积剂量>600 mg，罹患CAP与机会性感染（如PJP）的风险均增加，属于“真正的免疫抑制人群”。 3. 临床特征与预后临床研究显示，重症社区获得性肺炎（SCAP）中，免疫抑制宿主的主要诱因依次为长期激素使用（45%）、血液系统肿瘤（25%）、化疗（22%），而且活动性实体肿瘤与化疗、粒细胞缺乏，类固醇激素使用、血液肿瘤、生物制剂使用等危险因素之间均存在交叉重叠，47.9%的患者存在≥2种免疫抑制危险因素（如实体肿瘤合并化疗）。重症肺炎是导致免疫抑制患者入住ICU的主要原因，其中血液系统肿瘤患者SCAP死亡率高达38%～87%。此类患者如何诊治？我们要识别免疫抑制类型、判断是否为感染性肺炎、确定感染病原体，以及评估是否为耐药菌，后续才能采取有针对性的治疗。二、免疫抑制患者诊断急性呼吸衰竭的DIREC策略免疫抑制宿主ARF病因复杂，需结合临床、影像学与病原学综合判断，2020年Intensive Care Med 杂志发表的文章提出了DIRECT诊断策略，为临床决策提供系统框架。 1. 诊断免疫抑制患者ARF的一般注意事项（1）根据临床及影像学表现推测ARF最可能的病因选择诊断方法。（2）通过适当的诊断策略确认初始诊断，始终考虑鉴别诊断并进行排查。（3）所有怀疑合并呼吸道感染的免疫抑制患者均接受最低限度的检查：影像学、血液检查（血常规、肝肾功能、电解质、乳酸脱氢酶、凝血功能等），血培养、痰涂片及培养、心脏彩超、尿细菌抗原、病毒核酸检查等。（4）优先选择无创检查而非支气管镜和肺泡灌洗。【笔者认为，对于免疫抑制患者，在保障安全的前提下，尽量创造条件及时完善支气管镜检查，留取下呼吸道标本，指导临床治疗】（5）阳性结果不一定能诊断(假阳性, 定植)。（6）阴性结果有时候可以帮助诊断。（7）当初步判断某种疾病不可能时，首选阴性预测值高的检查。（8）当考虑某种疾病时，应选择高灵敏度的检查。（9）需考虑风险/收益比。（10）支气管镜检查可能会导致呼吸衰竭恶化，因此无创检查作为首选，若需要完善支气管镜检查，可给予经鼻高流量氧疗。【笔者观点如前所述】 2. DIRECT策略核心内容 DIRECT策略通过6个维度整合诊断信息，具体如表1所示。表1 DIRECT策略三、不同类型免疫抑制宿主感染病原体的特点免疫抑制宿主感染的病原体谱与免疫缺陷类型高度相关，且混合感染（细菌+真菌/病毒）比例高，需结合免疫状态与影像学精准判断。 1. 按免疫缺陷类型分类不同免疫细胞缺陷对应特定病原体谱，临床可据此缩小病原学排查范围：（1）B淋巴细胞缺陷的免疫功能低下宿主常见细菌性肺炎，病原体为肺炎链球菌、脑膜炎链球菌、流感嗜血杆菌。（2）T细胞缺陷的免疫功能低下宿主肺炎常见病原体为肺孢子菌、隐球菌、分枝杆菌和弓形虫。（3）中性粒细胞、巨噬细胞缺陷的免疫功能低下宿主肺炎常见病原体为病毒、曲霉、分枝杆菌、诺卡菌、毛霉和弓形虫。 2. 根据肺部CT表现识别病原体胸部CT特征可辅助提示病原体，临床需结合CT表现优化病原学检查（表2）。表2 胸部CT与病原体的关联 3. 免疫抑制宿主CAP病原体与混合感染 3.1 核心病原体免疫抑制宿主发生CAP的核心病原体有：①革兰阳性菌：肺炎链球菌，甲氧西林敏感金黄色葡萄球菌（MSSA），化脓性链球菌，其他链球菌；②革兰阴性菌：流感嗜血杆菌，卡他莫拉菌，肠杆菌科（大肠杆菌、克雷伯杆菌）；③非典型病原体：嗜肺军团菌，肺炎衣原体，肺炎支原体，立克次体；④呼吸道病毒：流感病毒，副流感病毒，冠状病毒，呼吸道合胞病毒，鼻病毒，腺病毒，人偏肺病毒。 3.2 特殊病原体还有一些特殊病原体能够使免疫抑制宿主发生CAP，包括：①细菌，肠杆菌科（包括ESBL+CRE），非发酵革兰阴性杆菌（如假单胞菌或不动杆菌），耐甲氧西林金黄色葡萄球菌（MRSA），诺卡菌，马红球菌；②分枝杆菌：结核分枝杆菌，非结核分枝杆菌；③病毒：巨细胞病毒，单纯疱疹病毒，水痘带状疱疹病毒；④真菌：肺孢子菌，曲霉属，毛霉属，组织胞浆菌属，隐球菌属，芽生菌属，球孢子菌属；⑤寄生虫：刚地弓形虫，粪类圆线虫。 3.3 特异性免疫功能缺陷感染病原体（表3）表3 特异性免疫功能缺陷相关感染的病原体 3.4 混合感染在SCAP中，病原学构成因患者是否存在免疫抑制状态呈现显著差异。从病原谱特征来看，无论是否存在免疫抑制，细菌均为最主要病原体；但免疫抑制宿主中，难治性耐药菌[如金黄色葡萄球菌、铜绿假单胞菌、耐碳青霉烯类肠杆菌科细菌（CRE）等]的占比明显升高，同时机会性感染（如真菌、病毒感染）的发生率也显著增加。值得关注的是，免疫抑制宿主的SCAP常以混合感染为突出特点，细菌、真菌与病毒的多重感染较为常见。因此，在病原学检测中若出现多种病原体共存的情况，需结合患者临床表现、影像学特征及检测标本的临床意义，综合判断检出菌是否为真正致病菌，避免将定植菌或无关病原体误判为致病原，以保障诊疗决策的精准性。四、病原学诊断方法及特点精准病原学诊断是免疫抑制宿主抗感染治疗的核心，需结合传统检测与分子诊断技术，提高检出率与时效性。 1. 常规诊断路径免疫抑制宿主SCAP的诊断路径见图1。图1 重症社区获得性肺炎呼吸道病原微生物实验室诊断路径图源：中华医学杂志, 2020, 100(19):1459-1464. 2. 不同检测方法的诊断价值不同标本与检测技术的诊断率差异显著，临床需优先选择高诊断价值的方法（表4）。表4 特殊病原体的诊断方法图源：中华医学杂志, 2020, 100(19):1459-1464. 3. 技术进展：mNGS的优势多项研究证实，BALF mNGS在免疫抑制宿主SCAP中的阳性率显著高于常规微生物检测（CMTs）。mNGS尤其适用于混合感染、罕见病原体（如诺卡菌）及耐药菌（如CRE）的诊断，可缩短病原学确诊时间至24～48 h。五、免疫抑制宿主重症肺部感染治疗策略免疫抑制宿主肺部感染的治疗应结合耐药风险评估与病原学结果个体化调整方案。 1. 经验性治疗的覆盖范围国外共识推荐：①如果免疫功能低下宿主罹患重症肺炎时，初始经验性治疗应覆盖耐药的G+菌或G-菌，如果病原学评估未发现MDRO，则应降阶梯治疗。②当免疫功能低下宿主过去12个月存在MRSA定植或感染史时，初始经验性治疗应覆盖MRSA。③当免疫功能低下宿主过去12个月存在耐药G-菌定植或感染史、此前曾住院使用广谱抗感染药物、气管切开、中心粒细胞缺乏或合并肺部基础疾病时，初始经验性治疗应覆盖耐药G-菌（包括铜绿假单胞菌）。 2. MDRO的治疗策略对于CAP患者感染MDRO风险的评估，可参考2021年BMJ杂志发表的文章中2008—2015年四项研究构建的评分体系（图2），这些体系从不同维度识别风险，助力临床医生判断是否需经验性覆盖耐药菌，以优化CAP抗感染治疗决策。若存在MDR病原体感染风险，初始治疗需考虑覆盖耐药菌。对于HAP/VAP患者，医生需判断其感染MDR病原体的可能性，以此指导是否选用更广谱或针对耐药菌的抗生素，从而提升抗感染治疗的精准性。图2 CAP中多重耐药菌的预测图源：BMJ, 2021 Dec 6:375:e065871. 2.1 MDRO定义与常见类型 MDRO指的是对通常敏感的常用的3类或3类以上抗菌药物同时呈现耐药的细菌。临床常见MDRO包括：耐甲氧西林金黄色葡萄球菌（MRSA），耐万古霉素肠球菌（VRE），产超广谱β-内酰胺酶（ESBLs）肠杆菌科细菌（如大肠埃希菌和肺炎克雷伯菌），耐碳青霉烯类肠杆菌科细菌，多重耐药铜绿假单胞菌（MDR-PA），多重耐药鲍曼不动杆菌（MDR-AB）。 2.2 主要MDRO的治疗方案（1）MRSA感染：推荐药物为糖肽类（万古霉素、去甲万古霉素、替考拉宁）或利奈唑胺。万古霉素等糖肽类和利奈唑胺大致等效。（2）VRE感染：推荐药物为利奈唑胺或替考拉宁。VRE较少引起肺部感染，需排除定植和污染。VRE对头孢菌素类等多种抗菌药物天然耐药，应结合药敏试验结果选择、替考拉宁仅用于VanB型VRE感染。（3）产ESBLs肠杆菌科细菌：轻中度感染，选择头霉素类、氧头孢烯类、β-内酰胺酶抑制剂合剂。中重度感染，选择碳青霉烯类，或联合治疗方案。联合治疗方案：碳青霉烯类+喹诺酮类或氨基糖苷类，β-内酰胺酶抑制剂合剂+喹诺酮类或氨基糖苷类。方案应结合药敏试验结果及个体因素选择，大部分仅需要单药治疗，仅少数严重感染需要联合用药。（4）CRE：建议优先使用头孢他啶-阿维巴坦治疗产丝氨酸碳青霉烯酶（包括KPC和OXA-48）CRE感染（弱推荐，极低质量证据）。建议优先使用头孢他啶-阿维巴坦联合氨曲南治疗产金属酶的CRE感染(弱推荐, 极低质量证据)。对于使用氨基糖苷类无禁忌证的CRE感染患者，建议使用阿米卡星等氨基糖苷类联合治疗方案(有条件推荐, 极低质量证据)。在CRE对磷霉素敏感或与联合药物具有协同抗菌作用情况下，建议采用磷霉素静脉制剂联合用药治疗CRE感染(有条件推荐, 极低质量证据)。（5）MDR-PA/“难治”耐药性铜绿假单胞菌（DTR-PA）治疗：对于铜绿假单胞菌引起的重症CAP，治疗选择β-内酰胺类+氟喹诺酮类/氨基糖苷类。对于铜绿假单胞菌引起的重症HAP/VAP，经验性治疗选择β-内酰胺酶抑制剂复合制剂、碳青霉烯类单药或联合下列药物中的一种：氟喹诺酮类，氨基糖苷类。有耐碳青霉烯铜绿假单胞菌（CRPA）或DTR-PA感染风险时可联合多黏菌素类（多黏菌素B、多黏菌素E）。目标治疗根据药敏试验结果制定治疗方案，优先选择肺组织浓度充分的药物，针对CRPA或DTR-PA，选择头孢洛扎-他唑巴坦、头孢他啶-阿维巴坦、亚胺培南-西司他丁-瑞来巴坦、美罗培南-法硼巴坦±氟喹诺酮类/氨基糖苷类，以多黏菌素类为基础的联合治疗。 2024年IDSA指南治疗建议：①当铜绿假单胞菌分离株对传统的非碳青霉烯类β-内酰胺药物和碳青霉烯类药物均敏感时，首选前者而非碳青霉烯类药物。对于对任何碳青霉烯类药物都不敏感但对传统β-内酰胺类药物敏感的铜绿假单胞菌感染，建议使用传统药物作为大剂量延长输注疗法。对于重症患者或铜绿假单胞菌分离物对碳青霉烯类耐药但对传统β-内酰胺类药物敏感的控制不佳的患者，使用铜绿假单胞菌对其敏感的新型β-内酰胺类药物也是一种合理的治疗方法。②采用头孢洛扎-他唑巴坦、头孢他定-阿维巴坦和亚胺培南-西司他丁-瑞来巴坦是治疗DTR-PA引起的尿道外感染的首选抗生素。对于由DTR-PA引起的尿道外感染，头孢德罗是另一种治疗选择。③如果已确认对头孢洛扎-他唑巴坦、头孢他定-阿维巴坦、亚胺培南-西司他丁-瑞来巴坦或头孢德罗敏感，则不建议对DTR-PA引起的感染采用联合抗感染疗法。（6）耐碳青霉烯类鲍曼不动杆菌(CRAB)—2024年IDSA指南治疗建议: ①使用包含舒巴坦类药物的抗生素方案治疗CRAB感染。首选方案舒巴坦-度洛巴坦联合碳青霉烯类。如果没有舒巴坦-度洛巴坦, 次选方案采用大剂量氨苄西林-舒巴坦(舒巴坦成分的日总剂量为9 g)联合至少一种其他药物(即多黏菌素B、米诺环素＞替加环素或头孢德罗)方案。②多黏菌素B可考虑与至少一种其他药物联合使用, 以治疗CRAB感染，因其药代动力学特性更好。③可考虑将大剂量米诺环素(200 mg q12h)或大剂量替加环素(200 mg负荷剂量, 随后100 mg q12h)与至少一种其他药物联合用于治疗CRAB感染。仅限于在其他药物无效、无法耐受或不可用的情况下使用依拉环素。不建议使用奥马环素治疗CRAB感染。④不建议将美罗培南或亚胺培南-西司他丁用于治疗CRAB感染, 与舒巴坦钠-度洛巴坦联合用药除外。⑤不建议将利福平或其他利福霉素用于治疗CRAB感染。 2024年中国《碳青霉烯类耐药革兰阴性菌感染的诊断、治疗及防控指南》推荐：建议根据患者的情况，选择替加环素为基础或多黏菌素为基础的联合抗菌治疗方案治疗CRAB引起的肺部感染（弱推荐，极低质量证据）。②建议使用舒巴坦或含舒巴坦的酶抑制剂复方制剂的联合治疗方案治疗CRAB感染（弱推荐，低质量证据）。但我国体外药敏显示鲍曼不动杆菌对头孢哌酮-舒巴坦的耐药率低于氨苄西林-舒巴坦）。含舒巴坦联合用药不适用于青霉素过敏者。对于CRAB感染，IDSA指南与我国指南推荐意见不一致，可能与IDSA指南纳入的雾化吸入相关文献数量更多有关。临床中还需根据具体情况选择合适的治疗方式。六、新型抗多重耐药菌药物目前针对多重耐药菌的新型治疗药物种类丰富，涵盖以下类别：①新型头孢菌素类：头孢洛林、头孢吡普、头孢德罗、头孢吡肟/恩美唑巴坦；②新型氟喹诺酮类：来法莫林、德拉沙星；③四环素衍生物：依拉环素、奥马环素；④糖肽类：奥利万星、达巴万星；⑤噁唑烷酮类：特地唑胺；⑥β-内酰胺酶抑制剂复方制剂：头孢洛生-他唑巴坦、头孢他啶-阿维巴坦、美罗培南-法硼巴坦、亚胺培南-瑞来巴坦、头孢他啶-阿维巴坦/氨曲南、氨曲南-阿维巴坦、舒巴坦-度洛巴坦。尽管部分药物在临床应用中仍存在可及性限制，但这类新型药物为免疫抑制患者多重耐药菌感染的治疗提供了全新选择，有望提升耐药感染的治疗精准性与有效性。七、病例分享 1. 病例1：ANCA相关性血管炎合并胸腺瘤（Good综合征）放疗后PJP感染 1.1 病例资料患者：39岁女性，因“咳嗽、咳痰1周”入院。2024年7月6日入院。既往史：2024年3月我院诊断“ANCA相关性血管炎”，予以强的松（起始30 mg/d，目前为15 mg/d）+吗替麦考芬酯胶囊治疗；2024年4月确诊胸腺瘤，于我院行30次放疗。辅助检查：WBC 3.67×109/L，LYM 0.27 G/L（↓），NEU% 88.4%，Hb 135 g/L，PLT 164 G/L。ESR 25 mm/h，hs-CRP 79.51 mg/L，PCT 0.08 ng/ml；LDH 327.3 U/L；NT-BNP 47.35 ng/L，cTNI 0.02 ng/ml。病原学：血深部真菌检测阴性。影像学：7月6日胸部CT示双肺多发斑片状磨玻璃影，上肺为著（图3）。图3 患者入院时胸部CT 明确病原学：BALF mNGS检出耶氏肺孢子菌（序列数1349）。 1.2 治疗过程初始治疗（7.6-7.10）：头孢哌酮舒巴坦+莫西沙星+甲泼尼龙20 mg qd，症状无改善。调整治疗（7.11-7.12）：头孢哌酮舒巴坦+莫西沙星，甲泼尼龙40 mg qd，磺胺960 mg q6h。呼吸衰竭加重转RCIU（7.13-7.21）：哌拉西林舒巴坦4.5 g q8h，磺胺960 mg q6h，卡泊芬净50 mg qd，甲泼尼龙40 mg q12h，胸腺肽胶囊10 mg q8h，丙种球蛋白10 g qd（5 d）。【对于Good综合征，单纯磺胺治疗往往效果不佳，定期行丙种球蛋白治疗能够改善患者的临床症状，降低病死率】 1.3 转归 7月21日后患者呼吸衰竭改善，8月9日复查胸部CT示磨玻璃影吸收（图4）。图4 患者胸部CT动态演变 2. 病例2：肾移植术后新冠合并CRE肺炎 2.1 病例资料患者：76岁男性，因“咳嗽咳痰10天，发热1天”于2023年5月13日入院。既往史：糖尿病病史10余年，口服阿卡波糖50 mg tid、瑞格列奈1 mg qd及胰岛素（具体不详）降糖治疗，血糖控制不详；2002年因右肾肿瘤行肾移植手术。术后长期口服环孢素50 mg bid、吗替麦考酚酯0.5 g bid、强的松5 mg qd抗排斥治疗。辅助检查：WBC 6.91 G/L，LYM 0.03 G/L，NEU% 82.7%，Hb 156 g/L，PLT 91 G/L；ESR 12 mm/h，IL-6 29.98 pg/ml。HbA1c 7.66%。病原学：新型冠状病毒核酸阳性，甲流及乙流核酸阳；痰培养示肺炎克雷伯菌（CRE株，对亚胺培南耐药）；胸部CT示双肺实变影。 2.2 诊疗过程与病情演变初始治疗（5.13-5.19）：给予哌拉西林他唑巴坦抗感染、奥司他韦抗病毒，继续环孢素、吗替麦考酚酯、强的松抗排斥治疗。症状未明显改善，后续新冠核酸转为阳性，肺部炎症进展。治疗调整（5.20-5.30）：抗感染方案维持哌拉西林他唑巴坦，加用阿兹夫定抗病毒，甲强龙抗炎，继续免疫抑制剂治疗。痰培养检出肺炎克雷伯菌（CRE株，多重耐药），对多种抗生素耐药。精准治疗（5.31-6.20）：抗感染升级为头孢他啶-阿维巴坦+氨曲南，抗病毒换用奈玛特韦/利托那韦、莫诺拉韦，加用丙种球蛋白免疫支持，减少免疫抑制剂用量。耐药菌与真菌双重挑战（6.21-7.11）：痰培养再次检出多重耐药革兰阴性杆菌，同时培养出白色念珠菌。抗感染调整为替加环素+多黏菌素B，加用氟康唑抗真菌，同时加用吡非尼酮抗纤维化，继续免疫抑制剂治疗。 2.3 转归 7月6日、7月9日新冠核酸连续阴性，7月16日复查胸部CT提示肺部炎症较前明显改善，患者感染控制，病情好转（图5）。图5 患者胸部CT对比八、总结免疫抑制患者因糖皮质激素、免疫抑制剂、化疗等多种因素的影响,其严重肺部感染风险呈上升趋势。此类患者肺部感染常存在多种病原体混合感染的情况, 临床需结合免疫抑制类型、病史、临床症状及CT特征等识别可能的病原体。在治疗方面, 除了抗感染治疗外, 抗炎及免疫重建治疗同样重要, 是整体治疗方案中不可替代的关键环节。在免疫抑制患者群体中, 针对免疫系统失衡状态的免疫调节治疗不仅能直接改善患者的感染抵抗力和身体耐受度, 还能间接提升其对原发病治疗的依从性与效果, 对降低患者并发症发生率、延长生存周期、提高生活质量均具有不可忽视的作用。针对免疫抑制宿主肺部感染需尽早启动经验性治疗, 鉴于病因学诊断极具挑战性, 应通过多种途径尤其是借助灌洗液tNGS/mNGS技术查找病原体, 以实现精准治疗。扫码看视频向下滑动查看参考文献 [1] Ramirez JA, Musher DM, Evans SE, et al. Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies[J]. Chest, 2020, 158(5):1896-1911. [2] Deinhardt-Emmer S, Chousterman BG, Schefold JC, et al. Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies[J]. Lancet Respir Med, 2025, 13(7):623-637. [3] Di Pasquale MF, Sotgiu G, Gramegna A, et al. Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients[J]. Clin Infect Dis, 2019, 68(9):1482-1493. [4] Van de Louw A, Mirouse A, Peyrony O, et al. Bacterial Pneumonias in Immunocompromised Patients[J]. Semin Respir Crit Care Med, 2019, 40(4):498-507. [5] Azoulay E, Russell L, Van de Louw A, et al. Diagnosis of severe respiratory infections in immunocompromised patients[J]. Intensive Care Med, 2020, 46(2):298-314. [6] Viñán Garcés AE, Sanabria-Herrera N, Duque S, et al. Severe community-acquired pneumonia in immunosuppressed patients admitted to the ICU[J]. Respir Med, 2025, 240:108014. [7] Zhao J, Zhuge R, Hu B, et al. Clinical impact of bronchoalveolar lavage fluid metagenomic next-generation sequencing in immunocompromised patients with severe community-acquired pneumonia in ICU: a multicenter retrospective study[J]. Infection, 2025, 53(5):1911-1927. [8] Wu X, Li Y, Zhang M, et al. Etiology of Severe Community-Acquired Pneumonia in Adults Based on Metagenomic Next-Generation Sequencing: A Prospective Multicenter Study[J]. Infect Dis Ther, 2020, 9(4):1003-1015. [9] 北京医学会检验医学分会. 重症社区获得性肺炎病原微生物实验室诊断专家共识[J]. 中华医学杂志, 2020, 100(19):1459-1464. [10] Chean D, Windsor C, Lafarge A, et al. Severe Community-Acquired Pneumonia in Immunocompromised Patients[J]. Semin Respir Crit Care Med, 2024, 45(2):255-265. [11] Zhao J, Sun Y, Tang J, et al. The clinical application of metagenomic next-generation sequencing in immunocompromised patients with severe respiratory infections in the ICU[J]. Respir Res, 2024, 25(1):360. [12] Cillóniz C, Torres A, Niederman MS. Management of pneumonia in critically ill patients[J]. BMJ, 2021, 375:e065871. [13] Zhang F, Cheng W. The Mechanism of Bacterial Resistance and Potential Bacteriostatic Strategies[J]. Antibiotics (Basel), 2022, 11(9):1215. [14] 中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J]. 中华结核呼吸杂志, 2016, 39(4):253-279. [15] 中华医学会呼吸病学分会感染学组. 中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)[J]. 中华结核和呼吸杂志, 2018, 41(4):255-280. [16] 产超广谱β内酰胺酶肠杆菌感染急诊诊疗中国专家共识组. 产超广谱β内酰胺酶肠杆菌感染急诊诊疗中国专家共识[J]. 中华急诊医学杂志, 2020, 29(12):1520-1526. [17] 中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识编写组, 中国医药教育协会感染疾病专业委员会, 中华医学会细菌感染与耐药防控专业委员会. 中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识[J]. 中华医学杂志, 2021, 101(36):2850-2860. [18] 曾玫, 夏君, 宗志勇, 等. 碳青霉烯类耐药革兰阴性菌感染的诊断、治疗及防控指南[J]. 中国感染与化疗杂志, 2024, 24(2):135-151. [19] 中华医学会呼吸病学分会感染学组. 中国铜绿假单胞菌下呼吸道感染诊治专家共识（2022年版）[J]. 中华结核和呼吸杂志, 2022, 45(8)：739-752. [20] Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)[J]. Clin Infect Dis, 2022, 75(2):187-212. 作者介绍唐以军主任医师、教授，博士生导师，国务院特殊津贴专家，加拿大博士后；十堰市太和医院党委书记、院长，呼吸内科学科带头人，呼吸疾病研究所所长；中国医院协会常务理事，中国人体健康科技促进会现代医院精益管理专业委员会副主任委员，湖北省医院协会副会长，湖北省医学会呼吸病学分会副主任委员；湖北省有突出贡献专家，湖北省第二届医学领军人才，全国五一劳动奖章获得者，全国先进工作者；先后获得国家及省部级基金项目近10项，获省级一等奖1项，三等奖3项。王梅芳十堰市太和医院呼吸与危重症医学科主任，博士，教授/主任医师，博士研究生导师；美国休斯敦大学访问学者，2023年十堰市科技创新领军人才，主要研究方向为肺癌真菌感染及间质性肺病；中国医师协会呼吸医师分会首届中青年医师工作委员会委员，中国医药教育协会肺部肿瘤专业委员会委员，中国医药教育协会介入微创呼吸分会常委，国家临床医学研究中心-中国呼吸肿瘤协作组湖北分会副主任委员，十堰市医学会呼吸病专业委员会专业委员会副主任委员，湖北省临床肿瘤学会肿瘤呼吸病学专家委员会第一届委员会副主任委员，湖北省医师协会呼吸病医师分会第一届委员会常委；作为负责人独立主持并完成厅局级以上各类项目4项，作为骨干成员参与国家自然科学基金重点项目/面上项目；获湖北省科技进步二等奖1项、三等奖2项、十堰市科技进步三等奖1项及国家发明专利1项。参编人卫版“十四·五"内科学专升本教材，参编2023版CACA指南。近5年，以第一作者或通讯作者共发表高水平SCI论文30余篇，中科院一区期刊发表论文7篇，单篇最高影响因子12.658，累计影响因子达100分以上。声明：本文仅用于学术领域的理论探讨与专业交流，不涉及任何商业推广、产品宣传等非学术用途，亦不作为临床诊疗活动中最终决策的依据。临床实践需根据患者的具体情况选择适宜的处理措施。

临床研究免疫疗法细胞疗法

2025-11-12

·摩熵医药

国内50款新药IND获批！9款品种过评，涉及石家庄四药、科伦制药……

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 PART 01 周报概述随着全球医药行业的快速发展，新药研发与创新已成为推动行业进步的重要动力。近期，根据摩熵医药数据统计，新药申请与审批获批频繁，显示出医药创新领域的活跃态势。本文将深入分析2025年11月03日至11月09日期间，国内外新药申请、临床试验批准、仿制药一致性评价等多个方面的最新进展，为用户提供全面的行业资讯。 PART 02 国内50款新药IND获批根据摩熵医药数据库统计，2025年11月3日至2025年11月9日期间，共有65个创新药/改良型新药临床申请/上市申请获国家药品监督管理局药品审评中心（CDE）承办（按受理号统计，不含补充申请）。其中国产药品受理号42个，进口药品受理号23个。本周共计50款创新药/改良型新药临床试验申请获得“默示许可”，包括化学药25款，生物药25款。本周获批临床创新药/改良型新药部分信息速览（不含补充申请）注：完整数据可识别“文末”二维码下载查看 PART 03 本周全球TOP10创新药研发进展 11月4日，CDE网站显示，复星医药自主研发的芦沃美替尼（曾用名：复迈替尼，研发代号：FCN-159）的新适应症拟纳入优先审评，用于2岁及2岁以上朗格汉斯细胞组织细胞增生症（LCH）儿童患者。截图来源：摩熵医药全球药物研发数据库 LCH是一种以丝裂原活化蛋白激酶信号通路激活为主要分子特征的克隆性血液系统肿瘤，可累及全身各器官及系统，临床表现多样。芦沃美替尼是复星医药自主研发的创新型小分子MEK1/2选择性抑制剂，通过阻断MAPK信号通路的异常激活，抑制肿瘤细胞增殖并诱导其凋亡。此前，芦沃美替尼已于今年5月获批上市，用于治疗LCH和组织细胞肿瘤成人患者；2岁及2岁以上伴有症状、无法手术的丛状神经纤维瘤（PN）的I型神经纤维瘤病（NF1）儿童及青少年患者。截图来源：摩熵医药全球药物研发数据库 11月5日，赛诺菲（Sanofi）宣布其创新药物注射用卡拉西珠单抗正式获得中国国家药品监督管理局（NMPA）批准，用于与血浆置换和免疫抑制疗法联合治疗获得性血栓性血小板减少性紫癜（aTTP，也称为免疫介导的血栓性血小板减少性紫癜[iTTP]）的成人和12岁及以上体重至少40kg的青少年患者。截图来源：摩熵医药全球药物研发数据库这一款靶向治疗iTTP的纳米抗体药物，可实现更快速的疾病控制，减少相关死亡、恶化或重大血栓性事件，预防复发，为患者提供更为高效、安全的治疗选择。据赛诺菲新闻稿，卡拉西珠单抗是全球首个且目前唯一获批用于aTTP治疗的新药。本周全球 TOP10 创新药研发进展截图来源：摩熵医药周报 PART 04 本周全球TOP10临床试验结果本周全球多项临床试验结果亮点纷呈。11月3日，罗氏宣布其Gazyva®/Gazyvaro®（奥妥珠单抗，CD20单抗）在针对接受标准疗法的系统性红斑狼疮（SLE）成年患者进行的III期ALLEGORY研究达到了主要终点和所有关键次要终点，结果显示Gazyva/Gazyvaro能够显著减少SLE的疾病活动性。截图来源：摩熵医药全球药物研发数据库 ALLEGORY研究是一项III期、随机、双盲、安慰剂对照、多中心研究，旨在评估Gazyva/Gazyvaro与标准疗法相比，在接受标准疗法的SLE成人患者中的疗效和安全性。该研究招募了约300人，受试者按1:1随机接受Gazyva/Gazyvaro或安慰剂治疗，持续52周，主要终点是达到SLE应答指数4（SRI-4）最低四点改善的患者百分比。结果显示，与标准疗法相比，Gazyva/Gazyvaro组在52周时达到这一主要终点的人群比例更高。SRI是一种评估疾病严重程度、症状和身体状况变化的工具，用于判断治疗是否有效控制了疾病活动。此外，所有关键次要终点也已达到，并且未发现新的安全信号，其安全性与Gazyva/Gazyvaro已知的良好特征一致。本周全球 TOP10 积极/失败临床结果截图来源：摩熵医药周报 PART 05 9款品种过评，涉及石家庄四药、科伦制药等药企根据摩熵医药数据库统计，2025年11月3日至2025年11月9日期间，共有70项仿制药申报上市/申报临床获CDE承办，其中新注册分类上市申请受理号59项（包括化药3类，4类），新注册分类临床申请受理号2项（包括化药3类），一致性评价申请9项。本周9个品种通过一致性评价（按受理号计12项）。本周有5项生物类似物注册申报动态，复星万邦（江苏）医药集团的司美格鲁肽注射液，成都康弘生物的KH816注射液，江苏景行医药的度普利尤单抗注射液，上海生物制品的注射用曲妥珠单抗以及东曜药业的贝伐珠单抗注射液。本周过评/视同过评品种主要为血液和造血系统药物；过评/视同过评产品剂型主要为注射剂。截图来源：摩熵医药周报本周注射用氨曲南、甘油磷酸钠注射液和那屈肝素钙注射液过评/视同过评受理号数量最多，达2个，本周所有品种过评/视同过评企业均为1家；本周所有企业过评/视同过评品种数均为1种，本周过评/视同过评企业共包括上海上药新亚药业、湖南科伦制药和南京健友生化制药等9家企业。截图来源：摩熵医药周报摩熵咨询本期完整周报识别二维码领取下载 END 本文为原创文章，转载请留言获取授权近期热门资源获取中国临床试验趋势与国际多中心临床展望-202505 2024年医药企业综合实力排行榜-202505 中国带状疱疹疫苗行业分析报告-202505 2023H2-2024H1中国药品分析报告-202504 数据透视：中药创新药、经典验方、改良型新药、同名同方的申报、获批、销售情况-202503 2024年中国1类新药靶点白皮书-202503 中国AI医疗健康企业创新发展百强榜单-202502 解码护肤抗衰：消费偏好洞察与市场格局分析-202502 2024年FDA批准上市的新药分析报告-202501 小分子化药白皮书（上）-202501 2024年中国医疗健康投融资全景洞察报告-202501 2024年医保谈判及市场分析报告-202501 近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

100 项与氨曲南相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00240	氨曲南	J01DF01	DB00355

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
囊性纤维化	美国	Gilead Sciences, Inc.	2010-02-22
革兰氏阴性菌感染	中国	中美上海施贵宝制药有限公司	1997-01-01
腹腔感染	美国	Bristol Myers Squibb Co.	1996-11-01
脑膜炎	日本	Eisai Co., Ltd.	1988-05-31
腹腔脓肿	日本	Eisai Co., Ltd.	1987-01-12
胆管炎	日本	Eisai Co., Ltd.	1987-01-12
胆囊炎	日本	Eisai Co., Ltd.	1987-01-12
膀胱炎	日本	Eisai Co., Ltd.	1987-01-12
出血性败血症	日本	Eisai Co., Ltd.	1987-01-12
子宫内感染	日本	Eisai Co., Ltd.	1987-01-12
角膜炎	日本	Eisai Co., Ltd.	1987-01-12
肺脓肿	日本	Eisai Co., Ltd.	1987-01-12
中耳炎	日本	Eisai Co., Ltd.	1987-01-12
腹膜炎	日本	Eisai Co., Ltd.	1987-01-12
肺炎	日本	Eisai Co., Ltd.	1987-01-12
前列腺炎	日本	Eisai Co., Ltd.	1987-01-12
肾盂肾炎	日本	Eisai Co., Ltd.	1987-01-12
鼻窦炎	日本	Eisai Co., Ltd.	1987-01-12
尿道炎	日本	Eisai Co., Ltd.	1987-01-12
宫颈炎	日本	Eisai Co., Ltd.	1987-01-12

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
传染性皮肤病	临床3期	-	Wyeth AB	2002-11-01
肺部感染	临床2期	美国	Gilead Sciences, Inc.	2003-06-01
假单胞菌感染	临床2期	美国	Gilead Sciences, Inc.	2003-06-01
细菌感染	临床1期	英国	Pfizer Inc.	2012-09-01
复杂的尿路感染	临床1期	英国	Pfizer Inc.	2012-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03978091 (Pubmed) 人工标引	临床1期	-	19	Aztreonam+Ceftazidime+Avibactam	醖範構鏇蓋壓憲衊淵壓(繭齋鹽鑰蓋獵鹹選積範) = 鏇築顧鑰網壓糧繭膚簾蓋觸範襯襯獵鹹鑰繭憲 (艱廠製艱觸壓糧醖構齋 ) 更多	积极	2022-11-17
NCT03867734 (CTgov)	临床2/3期	淋病 \| 淋菌性尿道炎 \| 咽疾病	32	Aztreonam	艱網簾顧艱襯願糧願製(築鏇製觸網鏇夢膚積網) = 積選鑰構積蓋齋廠壓窪夢衊夢糧築壓選艱蓋齋 (觸積鹽醖鏇鹹鹹衊製獵, 築鹹憲願窪膚艱襯齋獵 ~ 構鏇鬱範窪壓鹽構遞夢) 更多	-	2022-01-06
NCT03978091 (CTgov)	临床1/2期	细菌感染	48	AVYCAZ IV (AVYCAZ IV)	網觸衊積艱範築遞襯鹹 = 醖積製鹽簾憲齋餘構糧衊鑰艱製蓋遞鬱鹽糧壓 (蓋糧選獵繭構糧鑰網鏇, 鏇製繭構築蓋積齋膚鹽 ~ 壓構鹹鏇鹹顧窪憲觸餘) 更多	-	2021-12-23
				AVYCAZ (AVYCAZ CI)	網觸衊積艱範築遞襯鹹 = 鬱範觸遞積糧衊願憲築衊鑰艱製蓋遞鬱鹽糧壓 (蓋糧選獵繭構糧鑰網鏇, 顧觸簾構製鏇構簾廠繭 ~ 願製獵獵遞衊襯襯簾顧) 更多
NCT03158116 (A-PACT, CTgov)	临床4期	感染	5	Inhaled Aztreonam	鹽鹹築艱廠遞憲遞夢壓 = 鏇願憲願鹹顧鹽構積鏇憲糧觸壓鑰築廠衊廠鑰 (艱餘遞構醖襯遞遞襯構, 鹹築顧衊淵觸淵範顧壓 ~ 鬱鏇鹹構積遞襯窪鏇鏇) 更多	-	2021-07-30
NCT02730793 (CTgov)	临床2期	鼻部疾病 \| 囊性纤维化	5	Nasal Placebo+Oral Aztreonam (Standard Therapy)	窪衊廠鑰醖築繭淵鹽憲(築蓋齋膚鑰選願獵壓鑰) = 夢鹹鏇衊窪願簾糧願衊衊鏇壓襯衊憲淵願淵鏇 (齋廠艱獵繭鏇餘醖膚遞, 壓憲遞憲鑰艱鹽願遞膚 ~ 製鬱鹹膚簾製齋顧鬱壓) 更多	-	2021-01-12
				Oral Aztreonam (Study Therapy)	窪衊廠鑰醖築繭淵鹽憲(築蓋齋膚鑰選願獵壓鑰) = 願齋壓鹽膚願餘鏇積廠衊鏇壓襯衊憲淵願淵鏇 (齋廠艱獵繭鏇餘醖膚遞, 淵繭夢選齋網鹹鹹淵鑰 ~ 繭築醖鬱窪觸願壓範積) 更多
NCT03867734 (Pubmed \| Antimicrob Agents Chemother)	临床2/3期	淋病	32	Aztreonam 2g	積壓衊糧顧觸襯觸製鏇(齋鬱糧積醖鏇醖製範積) = 範範艱艱築構醖積積簾廠窪範積範獵積憲廠製 (獵積蓋衊鑰範淵遞鏇觸 ) 更多	-	2020-12-16
NCT01659866 (CTgov)	临床4期	感染	563	Ciprofloxacin (Cipro-susceptible)	蓋鏇憲網壓觸窪觸製鑰 = 壓鹽襯製夢觸壓鏇鹽夢積醖壓積構蓋廠壓觸範 (鬱憲觸獵觸繭鏇製願簾, 鹹構艱齋衊夢廠醖淵積 ~ 壓鬱夢蓋憲鑰蓋製築窪) 更多	-	2019-06-25
				imipenem+aztreonam+trimethoprim-sulfamethoxazole+cefuroxime+gentamicin+ceftriaxone+amikacin (Cipro-resistant)	蓋鏇憲網壓觸窪觸製鑰 = 糧簾壓顧鹽築艱壓憲糧積醖壓積構蓋廠壓觸範 (鬱憲觸獵觸繭鏇製願簾, 願願鹹鏇窪鏇膚鹹鹹壓 ~ 襯憲餘餘蓋製淵膚鹽選) 更多
NCT01375049 (ALPINE, Pubmed \| J Cyst Fibros)	临床2期	囊性纤维化	105	Aztreonam for inhalation solution (AZLI) 75 mg	蓋餘膚製鬱鹽鑰餘襯遞(廠憲獵築顧廠鹽鏇廠簾) = 淵壓構鑰齋衊願選願簾廠齋壓積襯繭鏇膚顧鑰 (製範憲憲網廠製範顧構 )	-	2015-01-01
NCT01375049 (ALPINE, CTgov)	临床2期	假单胞菌感染 \| 囊性纤维化	105	AZLI (AZLI - Evaluable Analysis Set)	獵膚膚願廠顧齋積艱齋 = 廠齋鹹蓋艱範積顧廠蓋衊夢壓網鹹膚選鑰衊襯 (遞願簾鏇齋製齋醖鑰鬱, 積選艱憲鹽網簾壓蓋鑰 ~ 獵衊醖餘顧壓衊範繭蓋)	-	2014-07-01
				AZLI - Met (AZLI - Met Primary Efficacy Endpoint)	簾襯蓋顧鏇衊鏇鹽艱鏇(積製築選醖夢構鹽鏇齋) = 構鹽廠遞餘鏇憲鹽壓簾網艱餘衊選鏇艱餘顧觸 (簾獵網糧衊觸願廠夢獵, 10.373) 更多
Pubmed \| Clin Infect Dis	临床3期	皮肤和皮肤结构感染	1,116	Tigecycline	積範鑰淵製窪壓衊鏇餘(衊憲遞顧願範鹽夢築繭) = increased nausea and vomiting in the tigecycline group 遞衊膚衊廠醖選艱艱醖 (壓觸範選鹽衊淵築壓鹹 ) 更多	-	2005-09-01
				Vancomycin-Aztreonam